Advances in Bioresearch
Adv. Biores., Vol 15 (1) January 2024: 417-426

Print ISSN 0976-4585; Online ISSN 2277-1573
Journal's URL:http://www.soeagra.com/abr.html
CODEN: ABRDC3
DOI: 10.15515/abr.0976-4585.15.1.417426

Advances in Bioresearch

REVIEW ARTICLE

A Systematic Review on Remdesivir for Preventing Covid 19

Indrakumar K. Sonawane[1], Khemchand R. Surana[2*], Deepak D. Sonawane[1], Yogesh P. Sharma[1], Dhananjay M. Patil[1]

[1] Department of Pharmaceutics, SSS's Divine College of Pharmacy, Nampur Road, Satana, Nashik, Maharashtra, India – 423301.

[2] Department of Pharmaceutical Chemistry, SSS's Divine College of Pharmacy, Nampur Road, Satana, Nashik, Maharashtra, India – 423301.

*Corresponding author: **Mr. Khemchand R. Surana,**
Email: khemchandsurana411@gmail.com
ORCID ID: https://orcid.org/0000-0001-8918-1159

ABSTRACT

The study's objective was to describe remdesivir's antiviral activity against COVID-19-causing SARS-CoV-2. Remdesivir protects animals with the illness by lowering the viral load and preventing the spread of the SARS-CoV-2 virus. Remdesivir also improves pulmonary lesions, decreases mild symptoms, and slows down the degenerative process in SARS-CoV-2-infected animals. Patients who have COVID-19 have been treated with remdesivir as a type of medication. Remdesivir has only been tested in vitro and in animal models for its potential effectiveness against coronaviruses. However, the amount of knowledge about COVID-19 is quickly expanding. Remdesivir is presently the subject of many clinical studies for the treatment of COVID-19. In this review, in light of an electronic pursuit of PubMed and different data sets, the highlights of remdesivir and its utilization for treating Coronavirus are analyzed.

Keywords: *Remdesivir, SARS-CoV-2, COVID-19, Antiviral.*

Received 24.10.2023 Revised 01.11.2023 Accepted 11.01.2024

How to cite this article:
Indrakumar K. Sonawane, Khemchand R. Surana, Deepak D. Sonawane, Yogesh P. Sharma, Dhananjay M. Patil.A Systematic Review on Remdesivir For Preventing Covid 19. Adv. Biores., Vol 15(2) March 2024: 417-426.

INTRODUCTION

The severe acute respiratory syndrome coronavirus (2019-nCoV), also known as the novel human infectious coronavirus (2019-nCoV), is officially referred to as SARS-CoV-2. The SARS-CoV-2 virus is what causes COVID-19, a disease [1, 2]. The end of 2019 saw Wuhan's earliest diagnosis of the illness, which spread quickly to other parts of the world. Because there are more contagious patients everywhere, there is currently a pandemic. It takes a long time to research, develop, and produce specific COVID-19 therapies and vaccines [3, 4]. Conventional medicine and alternative treatments like inflammation control, oxygen therapy, and hydration management may be helpful in managing the clinical indications of the infection, such as cough, fever, and breathing difficulties. The clinical symptoms of the infection, such as cough, fever, and breathing difficulties, can currently be managed [5, 6]. Almost 90% of the amino acid sequences in the two viruses' enzymes are similar. Because their RNA-dependent RNA polymerase (RdRp) sequences are 96% the same, treatments for SARS-CoV and the Middle East Respiratory Syndrome coronavirus (MERS-CoV) may also work for COVID-19 [7, 8]. Ribavirin, favipiravir, penciclovir, galidesivir, and remdesivir are a few therapies that can target RdRp in the genus Betacoronavirus. Acyclovir fleximer analogues and 6-fluorinated aristeromycin analogues are two additional options. Remdesivir (GS-5734), a drug evaluated in human clinical trials for the treatment of MERS-CoV and Ebola virus infections, has shown effectiveness [9, 10]. Remdesivir's potential has been demonstrated in both in vitro studies and animal models infected with the SARS and MERS coronaviruses [11]. In light of this, the drug could be successful in treating SARS-CoV-2. The features, functions, and uses of remdesivir in the treatment of COVID-19 are reviewed in this review [12]. Online searches were conducted using the "PubMed" and "Google Scholar" databases. Remdesivir, COVID-19, SARS-CoV-2, SARS-CoV, SARS-CoV,

MERS-CoV, pharmacodynamics, pharmacokinetics, dosing, adverse effects, RNA-dependent RNA polymerase, 2019-nCoV, Ebola virus, safety, "Mechanism of action," clinical trial, diagnosis, and intravenous administration were the most frequently searched for terms. There were no studies included that did not have a full text or had a title and abstract in English but a full text in another language [13, 14].

CHEMISTRY AND PHARMACOLOGY OF REMDESIVIR

The pro-drug version of GS-441524, a phosphoramidated 1′-cyanosubstituted nucleoside analogue, is called Remdesivir. By competing with endogenous nucleotides for inclusion in replicating viral RNA, RNA-dependent RNA polymerase (RdRp) prevents viral replication [15]. Wide-ranging antiviral drugs function admirably against the RdRp non-underlying protein (nsp12), which Covids share. Intracellular kinases quickly transform remdesivir inside cells into its active nucleoside triphosphate metabolite (GS-443902). In most cases, the rate-limiting step in the activation of nucleoside analogues is the production of nucleoside monophosphate. Because they are bioisosteres of monophosphates, emdesivir, and GS-441524, they can get out of this rate-limiting phase [16, 17]. To prevent the charged phosphonate group from being seen and to speed up cell entry, nucleoside phosphoramidates must be administered as pro-drugs [18]. The 2-ethylbutyl and L-alanine groups conceal Remdesivir's negative charge; however, intracellular esterase's rapidly decompose these groups. Additionally, the 1′-CN group of remdesivir and its metabolites makes them more selective for RdRp than human polymerases. Due to the unique exoribonuclease (ExoN) of coronaviruses, it has been challenging to develop nucleoside analogues that are effective against these pathogens [19]. ExoN functions as a proofreading enzyme, identifying mistakes as the RNA chain forms. For instance, ExoN has been blamed for ribavirin's ineffectiveness against coronaviruses in vitro. Even though Remdesivir can partially avoid proofreading and still display significant antiviral activity in the presence of ExoN, it exhibits higher antiviral efficacy against viruses that lack ExoN. A mouse hepatitis virus (MHV) model of the coronavirus expertly demonstrated this point. The remdesivir inhibitory sensitivity of 11 viruses lacking ExoN was around 4-times higher than that of wild-type MHV (EC50 0.087 mol/L). Due to two distinct characteristics, exoN seldom has an impact on Remdesivir's activity [20, 21]. To begin with, remdesivir integrates into the RNA replication process more effectively than natural nucleotides do. The preference of coronaviruses for remdesivir versus synthetic nucleotides was examined in multiple kinetic investigations, which demonstrated this [22]. For a single incorporation of a natural nucleotide over a nucleotide analogue, the parameters used to define selectivity in this context range from Vmax, which indicates the maximum velocity of nucleotide incorporation, to Km, which indicates the substrate concentration at which the incorporation velocity is half Vmax [23]. For a single incorporation of a natural nucleotide over a nucleotide analogue, the parameters used to define selectivity range from Vmax (which reflects the maximum velocity of nucleotide incorporation) to Km (which reflects the substrate concentration at which the incorporation velocity is half Vmax). It's interesting to note that the selectivity values for SARS-CoV-2 were greater for the Ebola virus (4) as well as for other nucleotide analogues (favipiravir = 570 and ribavirin >> 1000). By functioning as a delayed or non-obligate RNA chain terminator, Remdesivir partially evades ExoN [24]. When a nucleotide analogue is missing the free 3′-OH group needed for natural nucleotides to be inserted, chain termination is delayed. In any case, the addition of the postponed chain eliminator causes the RNA design to be upset, which eventually brings about the end of the combination. The presentation of remdesivir (GS-443902) dependably brings about the chain end of SARS-CoV-1, SARS-CoV-2, and MERS-CoV after three additional nucleotides have been acquainted with each of the three infections. Some reviews show that these nucleotides could offer protection against ExoN extraction [25, 26].



Figure 1: Structure of Remdesivir

MECHANISM OF ACTION

Remdesivir is a prodrug made from adenosine C-nucleoside phosphoramidate. It can get into human respiratory epithelial cells and turn into a nucleoside triphosphate, which is the active form. When a coronavirus is active, lung epithelial cells are unable to create other coronaviruses. RNA-dependent RNA polymerase (RdRp) is stopped from working by a nucleoside analogue called adenosine triphosphate (ATP), which is the natural opposite of the drug [27]. As the enzyme incorporates one, two, or three more nucleotides, the integrated nucleoside analogue slides back and slows viral reproduction. By integrating it into the RNA strand that is producing the nucleoside analogue, we postpone the end of viral replication. At a distance of three places from the active site, the medicine inhibits the enzyme. Because the active form of remdesivir interferes with a conserved serine (Ser) in the enzyme's active site and prevents it from moving one step further to incorporate the subsequent nucleotide, the virus's exoribonuclease, which normally checks and fixes replication errors, is unable to function against it [28, 29].



Figure 2: Mechanism of action of Remdesivir

Pharmacodynamics and Pharmacokinetics of Remdesivir

Documents released to the public by the US Food and Drug Administration (FDA) include a summary of the pharmacokinetics of remdesivir. Emdesivir, an unapproved medication, may now be used in an emergency to treat SARS-CoV-2 infections in adults and paediatric patients who have been admitted with life-threatening illnesses. This is thanks to the FDA's emergency use approval (EUA) [30]. Remdesivir is to

be administered intravenously (IV) over a 30- to 120-minute period, according to the EUA approved by the FDA. Adult patients will receive a first-day loading dose of 200 mg, followed by daily maintenance doses of 100 mg beginning on day 2. Depending on how much weight a child has, the product's dosage should be altered. For patients who require invasive mechanical breathing and/or ECMO, the treatment plan lasts 10 days, while for those who do not, it lasts 5 days. If a clinical improvement is not evident after the first seven days of treatment, Remdesivir may be given to patients who do not require invasive mechanical ventilation or ECMO for a total of 10 days [31, 32]. Contrarily, participants with severe COVID-19 who did not require mechanical ventilation were included in a recent study without a placebo control. (ClinicalTrials.gov number: NCT04292899). During a five- and ten-day timeframe, remdesivir treatment did not significantly alter the outcomes. Due to the absence of a placebo control group in the study, the level of Remdesivir's efficacy could not be evaluated. The trial's findings indicate that, if Remdesivir is an efficient medication, it might perhaps conserve scarce resources by being provided for shorter periods of time [33, 34]. Contrarily, a recent study (number: ClinicalTrials.gov) found that NCT04292899 included people who did not require mechanical ventilation but had severe COVID-19. The outcomes did not differ significantly between the 5-day and 10-day remdesivir doses. It was impossible to determine the degree of remdesivir efficacy in the trial because there was no placebo control arm. The trial's findings suggest that if remdesivir is a successful treatment, limited supplies could be conserved by using it for shorter periods of time. In addition to the testicles, eyes, and brain, the NTP has also been found in a number of other organs. Remdesivir (10 mg/kg) was administered intravenously once daily for twelve days to stop the virus from reproducing. By administering remdesivir even three days after the viral exposure, all infected monkeys were shielded from the fatal disease, and their clinical signs and pathophysiological markers were enhanced [35, 36]. Animal models and in vitro testing can both be used to assess Remdesivir's effectiveness against SARS-CoV-2 and related coronaviruses. In a mouse model of SARS-CoV infection, Remdesivir, for instance, has been shown to improve respiratory function and reduce viral load in the lungs when administered as early prophylaxis and therapy. 2020 looked into whether or not SARS CoV-2-infected Vero E6 cells could be treated with remdesivir. Remdesivir can be tested against SARS-CoV-2 and kindred coronaviruses in vitro and on animals to determine how effective it is. In a mouse model of SARS-CoV infection, for example, remdesivir has been shown to improve lung function and lower the amount of virus in the lungs when given as early prevention and treatment. 2020 looked at the effectiveness of remdesivir in treating Vero E6 cells that have SARS CoV-2 infection [37, 38].



Figure 3: Pharmacodynamics and Pharmacokinetics of Remdesivir

Adverse effects of the interventions administration of remdesivir:

Remdesivir: Remdesivir-related side effects were the subject of two studies involving 1281 patients. Both trials covered acute renal damage, but one study with 1048 patients covered cognitive impairment and delirium. There was no mention of any fatigue research [39].

Acute kidney injury: Because they focused on changes in blood creatinine rather than patient-important symptoms of acute kidney impairment, such as the requirement for renal replacement therapy, the studies lacked reliability [40].

Cognitive dysfunction/delirium: When compared to placebo, Remdesivir may have no effect on cognitive dysfunction or delirium at all (OR 1.22, 95% CI 0.48 to 3.11; RD 3 more for every 1000 people (95 percent CI 8 fewer to 32 more). The evidence's confidence level was low because of its severe indirectness, major imprecision (the idea of cognitive dysfunction or delirium was not established), and lack of systematic collection [41].

Applications of Remdesivir: Summary of Antiviral Activity against Different Viruses:

Gilead Sciences is the producer of the medication remdesivir (GS-5734). Gilead, the US Centers for Disease Control and Prevention (CDC), the US Army Medical Research Institute of Infectious Diseases (USAMRIID), and the three organizations identified RNA viruses like the Ebola virus, Middle East respiratory syndrome (MERS), and severe acute respiratory syndrome (SARS) coronaviruses that have the potential to spread internationally and cause pandemics. In order to find effective antiviral treatments for RNA viruses, a library of about 1,000 modified nucleosides was made [42]. This library includes prodrugs for monophosphate, ester, and phosphoramidate. Data screening findings revealed that two very potent antivirals, GS-441,524 (a 1-CN modified adenosine C-nucleoside hit) and GS-5734 (a prodrug form of the monophosphate of GS-441,524), were subsequently dubbed as remdesivir. Remdesivir was first used therapeutically against the Ebola virus in people in 2016. The discovery of Ebola virus RNA in the plasma and cerebral fluid made it possible to diagnose Ebola meningoencephalitis in a female nurse. Remdesivir and corticosteroids were successfully administered to the patient for two weeks (150 mg once daily, spaced out over two hours for two days, and then once daily for twelve days). No huge adverse consequences were seen regardless of a short ascent in serum levels of the chemical amylase [43]. In an observed, twofold visually impaired clinical concentration in the majority-rule Republic of the Congo, remdesivir was haphazardly given to 175 Ebola patients. Remdesivir did not work as a therapy since it had a high mortality rate (53.1%). However, some information was expressly obtained regarding the safety profile of remdesivir [44]. Comparatively to remdesivir, the survival rates were higher when two additional medications were administered. As a result, Remdesivir therapy randomization was postponed. Prominently, patients treated with single-portion antivirals, specifically MAb114 and REGN-EB3 cleared the infection more leisurely than the individuals who took remdesivir. The authors speculate that the need for repeated intravenous infusions of remdesivir may be responsible for this finding. Remdisiver has also been demonstrated to be effective in vitro in 2017 against bat and circulating modern human coronaviruses, in addition to its ability to stop the spread of SARS and MERS coronaviruses [45]. Mice were given remdesivir as a first-line treatment as well as a preventative measure. Reduced pulmonary viral loads, improved clinical signs and symptoms, and improved lung function were all outcomes of this. Remdesivir might someday be effective against coronaviruses, including newly emerging coronaviruses, circulating human coronaviruses, and the endemic MERS coronavirus. Studies on the anti-MERS therapeutic and preventative effects of remdesivir in rhesus macaques (a nonhuman primate model) were finished in 2020. According to the findings, treated animals had lower viral loads in their lungs than untreated animals. Animals getting therapeutic treatments experienced fewer severe injuries than that undergoing vehicle treatment [46]. The animals that had received preventive treatment had sound lungs. Overall, the results demonstrated remdesivir's efficiency in treating and preventing MERS. 19 Remdesivir and interferon-beta are more successful in combating MERS-CoV in vitro than lopinavir and ritonavir, according to research. Remdesivir reduced pulmonary viral loads and severe lung damage when given to mice either as a preventative measure or as a treatment. It also enhanced lung function. Then again, precautionary lopinavir/ritonavir-interferon beta treatment just somewhat diminished viral burdens without changing other infection-related factors. Using lopinavir, ritonavir, and interferon beta as a treatment, pulmonary function was improved while viral multiplicity and severe lung injury were reduced. The scientists' comprehensive study suggests that remdesivir may aid patients with coronavirus infections in recovering more rapidly, protect medical staff in locations where MERS is an endemic issue, and stop future coronavirus outbreaks [47].

Clinical Efficacy of Remdesivir to Treat COVID-19

Remdesivir's potential enemy of COVID viability has just been concentrated in vitro and utilised in creature models, although comprehension of the coronavirus is progressing rapidly. Following

pneumonia in the USA in January 2020, a COVID-19-positive 35-year-old man was humanely treated with intravenous remdesivir. The patient had intravenous remdesivir medication for his seven days in the hospital. The patient's condition appeared to be getting better on the ninth day [48]. Remdesivir administration was not linked to any negative outcomes. Remdesivir for COVID-19 may be provided prior to the completion of clinical investigations, according to research on the drug's compassionate use. There have been recounted reports of Remdesivir being utilised to treat Coronavirus patients. Remdesivir was used to treat 17 passengers on the Diamond Princess Cruise ship for ten days, according to a recent media report. The patients recovered completely. The number of patients requiring ventilators was reduced after the therapy was administered. But it should be made clear that conclusions should not be drawn from these results. A preprint on new medical research that focused on the first twelve COVID-19 patients in the United States covered the study [49]. The study was the subject of the preprint, despite the fact that it has not yet been confirmed and should not be used to guide treatment practice [50]. Along with demographic and clinical data on the patients, information was analysed on the progression of the infection and clinical treatment. In the second week, radiographic pneumonia symptoms and clinical or laboratory signs of deterioration necessitated the hospitalisation of seven of twelve patients (58 percent). Remdesivir, an experimental antiviral, was administered to three hospitalised patients for duration of four to ten days [51]. After taking remdesivir, the aminotransferase levels in all of the patients rose, and transient stomach symptoms such as nausea, vomiting, gastroparesis, and rectal haemorrhage were seen. No aftereffects of remdesivir were seen. The medication was discontinued once the respiratory difficulties subsided. According to research that was published in 2020, people with severe COVID-19 got remdesivir. The research comprised patients who had been diagnosed with SARS-CoV-2 and were either getting ambient air or breathing oxygen assistance. At least 94% of the subjects' blood did not have enough oxygen saturation. The drug administration lasted for ten days. Following an intravenously administered dose of 200 mg of the drug on the first day of the therapy cycle, the patients received 100 mg of remdesivir every day for the following nine days. 36 patients (68%) out of the 53 patients who were a part of the cohort trial saw clinical improvement [52]. The participant data of the study have already been discussed. used intravenous remdesivir in a placebo-controlled, double-blind, randomized study on COVID-19 patients. After receiving 200 mg of the medication intravenously on the first day of the therapy cycle, the patients received 100 mg of remdesivir daily for the following nine days. 36 patients (68%) out of the 53 patients who were a part of the cohort trial saw clinical improvement. The participant data of the study have already been discussed. used intravenous remdesivir in a placebo-controlled, double-blind, randomized study on COVID-19 patients [53]. In patients with severe COVID-19 who did not require mechanical ventilation, the intravenous remdesivir durations of five days and ten days were not significantly different. Since there was no placebo control group, it is impossible to determine the magnitude of the benefit (NCT04292899 on ClinicalTrials.gov). There was no significant difference between intravenous remdesivir administration for five days and ten days in patients with severe COVID-19 who did not require mechanical ventilation. Since there was no placebo control group, the size of the benefit cannot be determined (NCT04292899 on ClinicalTrials.gov). From the 237 patients, random groups were chosen to receive remdesivir (158 instances) and a placebo (79 cases). The outcomes showed no calculable variety in the time between the beginning of clinical improvement and the beginning of remdesivir medicine. But those who received remdesivir bounced back a lot faster than those who received a placeb [54].

Clinical trials:

Remdesivir is presently being evaluated for COVID-19 in a number of clinical investigations. In the USA, a placebo-controlled, double-blinded study is being conducted (ClinicalTrials.gov ID: NCT04280705). The two groups of patients are chosen at random, with one group receiving remdesivir and the other a placebo. Patients in the remdesivir group get a maintenance dosage (100 mg once daily) of the medication while inpatient for up to ten days following a starting dose of 200 mg parenteral remdesivir on day one. The length of recovery time is the primary finding of the experiment. The first day a patient satisfies one of the three conditions stated below on the ordinal scale is referred to as the patient's "day of recovery." One of three scenarios: 1) hospitalised, no longer needing home oxygen and ongoing medical care; 2) not hospitalised, activity limits or the need for home oxygen; or 3) not hospitalised, no activity restrictions. At the beginning of a certain study day, the clinical status is evaluated using an ordinal scale [55].

The US National Library of Medicine clinical trials registry described the seven-category scale as follows:

Death, hospitalisation with high-flow oxygen devices, invasive mechanical ventilation, ECMO, or noninvasive ventilation, or death Hospitalised with restrictions or hospitalised without any restrictions Patients with severe COVID-19 are being enrolled in a Gilead Sciences-funded phase 3 randomised clinical

trial to determine whether five or ten days of remdesivir are more effective. The trial number is NCT04292899 on ClinicalTrials.gov. The odds ratio for improvement is one of Day 14's key outcomes on a 7-point ordinal scale. Participants with mild COVID-19 have access to remdesivir in a different phase 3 randomised trial (NCT04292730; ClinicalTrials.gov identifier: NCT04292899). The proportion of patients who are discharged by day eleven is the primary outcome. The safety and efficacy of intravenous remdesivir were to be evaluated in two China-based double-blind, placebo-controlled studies. The focus of one experiment (identifier on ClinicalTrials.gov: 308 hospitalised patients with mild-to-moderate COVID-19 are the focus of one trial (NCT04252664), while 452 adult in patients with severe COVID-19 are the focus of another (NCT04257656) [56]. In both studies, the remdesivir regimen of ten days is used. The first day's dose is 200 mg, and each day after that, 100 mg are taken once. The duration of clinical recovery is the main finding of both trials. The span (estimated in hours) from the commencement of the review drug (dynamic or fake treatment) until standardization of temperature, respiratory rate, oxygen immersion, and hack alleviation supported for no less than 72 h or live emergency clinic discharge, whichever happens first, Remdesivir's efficacy and/or safety in treating COVID-19 are currently the subject of ten registered clinical trials [57].

Dosage and Administration

Remdesivir is available in two bioequivalent dosage forms: a lyophilized powder formulation and a concentrated solution (5 mg/mL). Remdesivir is available in preservative-free vials in 100-mg dosages. The FDA Fact Sheet is recommended for readers who want more specific instructions on how to store, prepare, and administer medications. For adults and children under 40 kilograms who require invasive mechanical ventilation or ECMO, the recommended dose is 200 mg intravenously on day one, followed by 100 mg intravenously once daily on days 2 through 10. For people who don't need intrusive mechanical breathing, or ECMO, a five-day routine is proposed. Scattering portions across a 30-to 2-hour window is fundamental. The FDA Fact Sheet should be consulted by readers if they want a complete list of paediatric dosing guidelines. Subcutaneous, intramuscular, or direct IV pushes are not covered in this article [58, 59].

CONCLUSION

More effectiveness evaluations in clinical studies are urgently required, despite the fact that remdesivir has demonstrated powerful antiviral activity. Scientists from small biotechnology startups to enormous pharmaceutical giants have collaborated to investigate and evaluate novel vaccines as the COVID-19 pandemic spreads worldwide. The quickest treatment method to stop the pandemic's spread is the reusing or repositioning of a powerful little particle drug, Remdesivir, one of the possible treatments, which has been fruitful in both in vitro and in vivo tests against COVIDs. Remdesivir recently offered proof in support of its capacity to support COVID-19 patients in need with a compassionate use prescription. In the Adaptive COVID-19 Treatment Trial (NCT04280705), Remdesivir-treated patients recovered 31% faster than control patients, indicating progress towards the primary objective. The use of remdesivir in the treatment of COVID-19 patients in hospitals has been granted approval by the U.S. Food and Drug Administration on the basis of these preliminary results. Since no medication has ever received FDA approval for commercialization as a treatment, this is the first experimental therapy approved for use in treating SARS-CoV-2. One medication that has just been approved for usage, remdesivir, may, in part, alleviate the COVID-19-related morbidity, mortality, and burden on the world's healthcare systems. However, more recent clinical trials will provide much-needed clarification regarding the repurposing of approved drugs and investigational treatments against SARS-CoV-2.

REFERENCES

1. Izcovich, A., Siemieniuk, R. A., Bartoszko, J. J., Ge, L., Zeraatkar, D., Kum, E., ... & Brignardello-Petersen, R. (2022). Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials. *BMJ open*, *12*(3), e048502.
2. Eastman, R. T., Roth, J. S., Brimacombe, K. R., Simeonov, A., Shen, M., Patnaik, S., & Hall, M. D. (2020). Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. *ACS central science*, *6*(5), 672-683.
3. Gulyaeva, A. A., & Gorbalenya, A. E. (2021). A nidovirus perspective on SARS-CoV-2. *Biochemical and biophysical research communications*, *538*, 24-34.
4. Vianello, C., Strozzi, F., Mocellin, P., Cimetta, E., Fabiano, B., Manenti, F., ... & Maschio, G. (2021). A perspective on early detection systems models for COVID-19 spreading. *Biochemical and biophysical research communications*, *538*, 244-252.
5. Intawong, K., Olson, D., & Chariyalertsak, S. (2021). Application technology to fight the COVID-19 pandemic: Lessons learned in Thailand. *Biochemical and biophysical research communications*, *534*, 830-836.

6. Liang, C., Tian, L., Liu, Y., Hui, N., Qiao, G., Li, H., ... & Zhao, X. (2020). A promising antiviral candidate drug for the COVID-19 pandemic: A mini-review of remdesivir. *European journal of medicinal chemistry*, *201*, 112527.
7. Platto, S., Zhou, J., Wang, Y., Wang, H., & Carafoli, E. (2021). Biodiversity loss and COVID-19 pandemic: The role of bats in the origin and the spreading of the disease. *Biochemical and biophysical research communications*, *538*, 2-13.
8. Moore, K. M., & Suthar, M. S. (2021). Comprehensive analysis of COVID-19 during pregnancy. *Biochemical and biophysical research communications*, *538*, 180-186.
9. Kenny, G., & Mallon, P. W. (2021). COVID19-clinical presentation and therapeutic considerations. *Biochemical and biophysical research communications*, *538*, 125-131.
10. Walsh, M. A., Grimes, J. M., & Stuart, D. I. (2021). Diamond Light Source: contributions to SARS-CoV-2 biology and therapeutics. *Biochemical and Biophysical Research Communications*, *538*, 40-46.
11. Jorgensen, S. C., Davis, M. R., & Lapinsky, S. E. (2022). A review of remdesivir for COVID-19 in pregnancy and lactation. *Journal of Antimicrobial Chemotherapy*, *77*(1), 24-30.
12. Chakraborty, S. (2021). Evolutionary and structural analysis elucidates mutations on SARS-CoV2 spike protein with altered human ACE2 binding affinity. *Biochemical and biophysical research communications*, *538*, 97-103.
13. Giovanetti, M., Benedetti, F., Campisi, G., Ciccozzi, A., Fabris, S., Ceccarelli, G., ... & Ciccozzi, M. (2021). Evolution patterns of SARS-CoV-2: Snapshot on its genome variants. *Biochemical and biophysical research communications*, *538*, 88-91.
14. Amin, S. A., & Jha, T. (2020). Fight against novel coronavirus: a perspective of medicinal chemists. *European Journal of Medicinal Chemistry*, *201*, 112559.
15. Jackson, C. B., Zhang, L., Farzan, M., & Choe, H. (2021). Functional importance of the D614G mutation in the SARS-CoV-2 spike protein. *Biochemical and Biophysical Research Communications*, *538*, 108-115.
16. Zinzula, L., Basquin, J., Bohn, S., Beck, F., Klumpe, S., Pfeifer, G., ... & Baumeister, W. (2021). High-resolution structure and biophysical characterization of the nucleocapsid phosphoprotein dimerization domain from the Covid-19 severe acute respiratory syndrome coronavirus 2. *Biochemical and biophysical research communications*, *538*, 54-62.
17. Mourier, T., Sadykov, M., Carr, M. J., Gonzalez, G., Hall, W. W., & Pain, A. (2021). Host-directed editing of the SARS-CoV-2 genome. *Biochemical and biophysical research communications*, *538*, 35-39.
18. Carrillo, J., Izquierdo-Useros, N., Ávila-Nieto, C., Pradenas, E., Clotet, B., & Blanco, J. (2021). Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity. *Biochemical and biophysical research communications*, *538*, 187-191.
19. Reznikov, L. R., Norris, M. H., Vashisht, R., Bluhm, A. P., Li, D., Liao, Y. S. J., ... & Ostrov, D. A. (2021). Identification of antiviral antihistamines for COVID-19 repurposing. *Biochemical and biophysical research communications*, *538*, 173-179.
20. Watashi, K. (2021). Identifying and repurposing antiviral drugs against severe acute respiratory syndrome coronavirus 2 with in silico and in vitro approaches. *Biochemical and Biophysical Research Communications*, *538*, 137-144.
21. Baxter, C., Karim, Q. A., & Karim, S. S. A. (2021). Identifying SARS-CoV-2 infections in South Africa: Balancing public health imperatives with saving lives. *Biochemical and Biophysical Research Communications*, *538*, 221-225.
22. Bacca, E., Digaetano, M., Meschiari, M., Franceschini, E., Menozzi, M., Cuomo, G., & Mussini, C. (2021). Immunomodulation for the management of severe SARS-CoV2 infections. State of the art and review of the literature. *Biochemical and Biophysical Research Communications*, *538*, 151-155.
23. Gaikwad, J., Jogdand, S., Pathan, A., Mahajan, A., Darak, A., Ahire, E. D., & Surana, K. R. (2023). Nutraceuticals Potential of Fat-Soluble Vitamins. *Vitamins as Nutraceuticals: Recent Advances and Applications*, 107-128.
24. Lai, C. K., & Lam, W. (2021). Laboratory testing for the diagnosis of COVID-19. *Biochemical and biophysical research communications*, *538*, 226-230.
25. McDonald, S., Turner, S., Page, M. J., & Turner, T. (2022). Most published systematic reviews of remdesivir for COVID-19 were redundant and lacked currency. *Journal of clinical epidemiology*, *146*, 22-31.
26. AHIRE, E. D., SURANA, K. R., SONAWANE, V. N., TALELE, S. G., KSHIRSAGAR, S. J., LADDHA, U. D., & TALELE, G. S. (2023). Role of Synthetic Medicines as Immunomodulators for the Cure of COVID-19. *COVID-19 and Immunomodulation with Special Emphasis on Nutraceutical and Herbal Formulation*.
27. Surana, K. R., Parkhe, A. G., Ahire, E. D., Pawar, A. R., Khairnar, S., Mahajan, S. K., ... & Kshirsagar, S. J. (2022). Current Therapeutic Targets for Neuropathic Pain. *Asian Journal of Pharmaceutical Research*, *12*(1), 96-104.
28. Fantini, J., Chahinian, H., & Yahi, N. (2021). Leveraging coronavirus binding to gangliosides for innovative vaccine and therapeutic strategies against COVID-19. *Biochemical and biophysical research communications*, *538*, 132-136.
29. Zinzula, L. (2021). Lost in deletion: The enigmatic ORF8 protein of SARS-CoV-2. *Biochemical and biophysical research communications*, *538*, 116-124.
30. Surana, K., Ahire, E. D., Pawar, R., Khairnar, R., Mahajan, S., Kshirsagar, S., ... & Keservani, R. K. (2022). Oral Health and Prebiotics. *Prebiotics and Probiotics in Disease Regulation and Management*, 291-309.
31. Lokhande, T. N., Varma, K. S., Gharate, S. M., Mahajan, S. K., & Surana, K. R. (2023). Vitamins as Nutraceuticals for Pregnancy. *Vitamins as Nutraceuticals: Recent Advances and Applications*, 185-204.

32. Lehmann, K. C., Gulyaeva, A., Zevenhoven-Dobbe, J. C., Janssen, G. M., Ruben, M., Overkleeft, H. S., ... & Gorbalenya, A. E. (2015). Discovery of an essential nucleotidylating activity associated with a newly delineated conserved domain in the RNA polymerase-containing protein of all nidoviruses. *Nucleic acids research*, *43*(17), 8416-8434.
33. Hasegawa, T., & Nemoto, K. (2017). Efficiency of prompt quarantine measures on a susceptible-infected-removed model in networks. *Physical review e*, *96*(2), 022311.
34. Dubey, P., Reddy, S. Y., Manuel, S., & Dwivedi, A. K. (2020). Maternal and neonatal characteristics and outcomes among COVID-19 infected women: An updated systematic review and meta-analysis. *European Journal of Obstetrics & Gynecology and Reproductive Biology*, *252*, 490-501.
35. Bellosta, R., Luzzani, L., Natalini, G., Pegorer, M. A., Attisani, L., Cossu, L. G., ... & Piffaretti, G. (2020). Acute limb ischemia in patients with COVID-19 pneumonia. *Journal of vascular surgery*, *72*(6), 1864-1872.
36. Surana, K. R., & Mahajan, S. K. (2022). In silico Study of Chromane Ring Compound Rubranonoside from Plumeria rubra as Anticancer Potential. *Trends in Sciences*, *19*(24), 3305-3305.
37. Sterne, J. A., Murthy, S., Diaz, J. V., Slutsky, A. S., Villar, J., Angus, D. C., ... & Marshall, J. C. (2020). Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. *Jama*, *324*(13), 1330-1341.
38. Rathnayake, A. D., Zheng, J., Kim, Y., Perera, K. D., Mackin, S., Meyerholz, D. K., ... & Chang, K. O. (2020). 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV–infected mice. *Science translational medicine*, *12*(557), eabc5332.
39. Schoof, M., Faust, B., Saunders, R. A., Sangwan, S., Rezelj, V., Hoppe, N., ... & Manglik, A. (2020). An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. *Science*, *370*(6523), 1473-1479.
40. Dande, R., Qureshi, A., Persaud, K., Puri, C., Zulfiqar, S., & Awasthi, S. (2021). Remdesivir in a pregnant patient with COVID-19 pneumonia. *Journal of community hospital internal medicine perspectives*, *11*(1), 103-106.
41. Ahire, E. D., Sonawane, V. N., Surana, K. R., Jadhav, K. R., Sonawane, D. D., & Shah, A. A. (2020). Convalescent plasma therapy: A promising approach in the treatment of Covid-19. *Int J Pharm Sci Res*, *11*, 4078-4086.
42. Khalil, A., Von Dadelszen, P., Draycott, T., Ugwumadu, A., O'Brien, P., & Magee, L. (2020). Change in the incidence of stillbirth and preterm delivery during the COVID-19 pandemic. *Jama*, *324*(7), 705-706.
43. Wang, Y., Zhang, D., Du, G., Du, R., Zhao, J., Jin, Y., ... & Wang, C. (2020). Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. *The lancet*, *395*(10236), 1569-1578.
44. Ahire, E. D., Sharma, N., Gupta, P. C., Khairnar, S., Surana, K., Ahire, B., ... & Kshirsagar, S. (2022). Developing Formulations of Prebiotics and Probiotics. *Prebiotics and Probiotics in Disease Regulation and Management*, 271-290.
45. Das, R. R., Jaiswal, N., Dev, N., Jaiswal, N., Naik, S. S., & Sankar, J. (2020). Efficacy and safety of anti-malarial drugs (chloroquine and hydroxy-chloroquine) in treatment of COVID-19 infection: a systematic review and meta-analysis. *Frontiers in medicine*, *7*, 482.
46. Talele, S. G., Ahire, E. D., Surana, K. R., Sonawane, V. N., & Talele, G. S. (2022). Corona Virus Disease (COVID-19): A past and Present Prospective. *Asian Journal of Pharmaceutical Research*, *12*(1), 45-53.
47. Devaux, C. A., Rolain, J. M., Colson, P., & Raoult, D. (2020). New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?. *International journal of antimicrobial agents*, *55*(5), 105938.
48. Kannan, S. R., Spratt, A. N., Quinn, T. P., Heng, X., Lorson, C. L., Sönnerborg, A., ... & Singh, K. (2020). Infectivity of SARS-CoV-2: there is something more than D614G?. *Journal of Neuroimmune Pharmacology*, *15*, 574-577.
49. Pathan, A., Mahajan, M. M., Jain, P. G., Zambad, S. P., Bhandari, G. S., Darak, A. D., ... & Surana, K. R. (2023). Nutraceutical Properties of Seaweed Vitamins. *Vitamins as Nutraceuticals: Recent Advances and Applications*, 167-184.
50. Harris, R. S., & Dudley, J. P. (2015). APOBECs and virus restriction. *Virology*, *479*, 131-145.
51. Dyall, J., Gross, R., Kindrachuk, J., Johnson, R. F., Olinger Jr, G. G., Hensley, L. E., ... & Jahrling, P. B. (2017). Middle East respiratory syndrome and severe acute respiratory syndrome: current therapeutic options and potential targets for novel therapies. *Drugs*, *77*(18), 1935-1966.
52. Jeon, S., Ko, M., Lee, J., Choi, I., Byun, S. Y., Park, S., ... & Kim, S. (2020). Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. *Antimicrobial agents and chemotherapy*, *64*(7), 10-1128.
53. Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., ... & Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The lancet*, *395*(10223), 497-506.
54. Parkhe, A. G., Surana, K. R., Ahire, E. D., Mahajan, S. K., Patil, D. M., & Sonawane, D. D. (2023). Impact of Vitamins on Immunity. *Vitamins as Nutraceuticals: Recent Advances and Applications*, 87-106.
55. Ahire, E. D., Sonawane, V. N., & Surana, K. R. (2020). Role of drug repurposing in current treatment strategies against COVID-19; systemic review. *Pharm Reson*, 24-9.
56. Chi, X., Yan, R., Zhang, J., Zhang, G., Zhang, Y., Hao, M., ... & Chen, W. (2020). A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. *Science*, *369*(6504), 650-655.
57. Ahire, E. D., Keservani, R. K., Surana, K. R., Singh, S., & Kesharwani, R. K. (Eds.). (2023). Vitamins as Nutraceuticals: Recent Advances and Applications.
58. Surana, K. R., Ahire, E. D., Sonawane, V. N., Talele, S. G., & Talele, G. S. (2021). Molecular modeling: Novel techniques in food and nutrition development. *Natural Food Products and Waste Recovery*, 17-31.
59. Surana, K. R., Ahire, E. D., Sonawane, V. N., Talele, S. G., & Talele, G. S. (2021). Informatics and methods in nutrition design and development. *Natural Food Products and Waste Recovery*, 33-49.

The Male Albino rats were split up into the subsequent seven sets of 6 animals respectively:

1. Yakubu MT, Sunmonu TO, Lewu FB, Ashafa AOT, Olorunnuji FJ, Eddouks M, (2015). Medicinal plants used in the management of diabetes mellitus. Evidence-based complementary and Alternative Medicine. 012038
2. Sahaya S, Soosainayagom, Janakiraman N, Johnson MAA. (2016). Anti-Bacterial Efficacy of *Vitex altissima International Journal of Engineering and Bioscience*. 3(3):79-86.
3. Mandal S, Vishvakarma P. Nanoemulgel: (2023). A Smarter Topical Lipidic Emulsion-based Nanocarrier. Indian J of Pharmaceutical Education and Research. 57(3s):s481-s498.
4. Mandal S, Jaiswal DV, Shiva K. (2020). A review on marketed *Carica papaya* leaf extract (CPLE) supplements for the treatment of dengue fever with thrombocytopenia and its drawback. International Journal of Pharmaceutical Research. 12(3).23-28
5. Mandal S, Bhumika K, Kumar M, Hak J, Vishvakarma P, Sharma UK. (2024). A Novel Approach on Micro Sponges Drug Delivery System: Method of Preparations, Application, and its Future Prospective. Indian J of Pharmaceutical Education and Research. ;58(1):45-63.
6. Parasuram S, Raveendran R, Keesavan R. (2010). Blood sample collection in small laboratory animals. Journal of Pharmacology and Pharmacotherapeutics. 1:87-93.
7. Pellegrino M, Christopher B, Michelle M. (1998). Diabetes. 47:224-230.
8. Pierre W Gildas AJH, Ulrich MC, Modeste W-N, Benoit NT, Albert K. (2012). Hypoglycemic and Hypolipidemic effects of *Bersama engleriana* leaves in Nicotinamide/Streptozotocin-induces type 2 diabetic rats. BMC Complementary Medicine and Therapies. 12:6.
9. Badole SL, Bodhankar SL. (2010). Antidiabetic activity of cycloart-23-ene-3beta,25 diol(B2) isolated from *Pongamia pinnata* (L Pierre) in Streptozotocin – Nicotinamide induced diabetic mice. European Journal of Pharmacology. 632:103-109.
10. Wang W, He Y, Lin P, Li Y, Sun R, Gu W, Yu J, Zhao R. (2014). In vitro effects of active components of polygonum multi-florum Radix on enzymes involved in the lipid metabolism. Journal of Ethnopharmacology. 153:763-770.
11. Ram Mohan Manda, Ganapaty Seru. (2015). Hypoglycaemic activity of the leaves of *Mimosa rubicaulis* (Lam). European Journal of Biomedical and Pharmaceutical Sciences. 2 (1), 543-548.